Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-Ribose) polymerase

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 2, 1998, Pages 884-893

  Tentori, Lucio ^a   Lacal, Pedro Miguel ^b   Benincasa, Elena ^a,b,c   Franco, Daniela ^a   Faraoni, Isabella ^a   Bonmassar, Enzo ^a   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; 7 METHYLGUANINE; PROTEIN BAX; PROTEIN P53; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031863682     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Baker SJ, Markowitz S, Fearon ER, Willison JKV and Volgestein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915.
2. Banerjee D, Lenz HJ, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Danenberg P and Bertino JR (1995) Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL-60 cells and increases their sensitivity to stress. Cell Growth Differ 6:1405-1413.
3. Barnes DE, Lindahl T and Sedgwick B (1993) DNA repair. Curr Opin Cell Biol 5:424-433.
4. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J and Jones RJ (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148-1158.
5. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M and Stevens MF (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913.
6. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin NJ, Golding BT and Durkacz. BW (1995) Potentiation of temozolomide induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 72:849-856.
7. Chomczynski P and Sacchi N (1987) Single step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal Biochem 162:156-159.
8. 6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukemic patients. Ann Oncol 6:389-393.
9. Diller L, Kassel F, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker M, Volgestein SJ and Friend SH (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781.
10. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87:5368-5372.
11. Dou QP, An B and Will PL (1995) Induction of retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci USA 92:9019-9023.
12. 6 benzylguanine. Cancer Res 56:5571-5575.
13. Franchi A, Papa G, D'Atri S, Piccioni D, Masi M and Bonmassar E (1992) Cytotoxic effects of Dacarbazine in patients with acute myelogenous leukemia: a pilot study. Haematologica 77:146-150.
14. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM and Dalla-Favera R (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia Proc Natl Acad Sci USA 88:5413-5417.
15. Griffin RJ, Curtin NJ, Newell DR, Goldin BT, Durkacz BW and Calvert AH (1995) The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 77:408-422.
16. Hansen R and Oren M (1997) p53; from inductive signal to cellular effect. Curr Opin Gen Dev 7:46-51.
17. 6-Methylguanine-DNA methyltransferase gene. Cancer Res 56:2029-2032.
18. Hollestein M, Sidransky D, Vogelstein B and Harris C (1991) p53 mutations in human cancers. Science 253:49-53.
19. Hollestein M, Rice K, Greenblatt MS, Soussi T, Fucks R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R and Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cells lines. Nucleic Acids Res 22:3551-3555.
20. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyozumi S, Seyama T (1996) Gain of function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res 56:3862-3865.
21. Jlang B, Bawr B, Hslang Y, Shen T, Potmesil M and Silber R (1989) Lack of drug induced DNA cross-links in chlorambucil-resistant Chinese hamster ovary cells. Cancer Res 49:5514-5517.
22. Karran P and Bignami M (1992) Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 20:2933-2940.
23. Karran P and Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioassays 16:833-839.
24. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Partecipation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
25. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM and Modrich P (1993) An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90:6424-6428.
26. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976-3985.
27. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Gene Dev 10:1054-1072.
28. Kumar S and Lavin F (1996) The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ 3:255-277.
29. 6 alkylguanine-DNA alkyltransferase by antitumor triazene compounds. J Pharmacol Exp Ther 279:416-422.
30. Lamb P and Crawford L (1986) Characterization of the human p53 gene. Mol Cell Biol 6:1379-1385.
31. Lindahl T, Satoh MS, Poirier GG and Klungland A (1995) Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. TIBS 20:405-411.
32. Liu L, Markovitz S and Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56:5375-5379.
33. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
34. Lowe ST, Bodis T, McClatchey A, Remington L, Ruley DE, Fisher DE, Housman T, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.
35. Margison GP, Cooper DP and Brennan J (1985) Cloning of the E. Coli O6-methylguanine and methylphosphotriester methyl transferase gene using a funcional DNA repair assay. Nucleic Acids Res 13:1939-1952.
36. Marx J O New link found between p53 and DNA repair. Science 266:1321-1322 (1994).
37. Miller DA and Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980-986.
38. Miyashita T, Krajewski S, Krajewska MH, Wang G, Lin HK, Liberman DA, Hoffman B and Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805.
39. Miyashita T and Reed JC (1995) Tumor Suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
40. 6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis 9:45-49.
41. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFC, Brampton MH and Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer 65:287-291.
42. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279.
43. 6 alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223.
44. Pocard M, Chevillard S, Villaudy J, Poupon MF, Dutrillaux B and Remvikos Y (1996) Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene 12:875-882.
45. Satoh MS and Lindahl T (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356:356-358.
46. 6-alkylguanine-DNA alkyltransferase deficient leukemic cell lines. Leukemia 9:1888-1895.
47. 6-alkylguanine DNA-alkyltransferase or poly (ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 52:249-258.
48. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM (1995) Yama/CPP32b, a mammalian homologue of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 81:801-809.
49. 3H)-one [CCRG81045; M and B 39831, NSC 362836] on poly(ADP ribose) metabolism. Br J Cancer 52:789-792.
50. 1-deoxyguanosinyl]-ethane, in DNA treated with N, N1-bis(2 chloroethyl)-N-nitrosoureas (BCNU). Cancer Res 42:3102-3105.
51. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Friedberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K and Harris CC (1995a) p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet 10:188-193.
52. Wang Y, Okan I, Szekely L, Klein G and Wiman KG (1995b) bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and bax. Cell Growth Differ 6:1071-1075.
53. 6 alkylguanine-DNA-alkyltransferse activity. Br J Cancer 74:1030-1036.
54. White E (1996) Life, death, and the pursuit of apoptosis. Genes Dev 10:1-15.
55. Wolf D and Rotter W (1985) Major deletion in the gene encoding the p53 gene tumor antigen causes lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82:790-794.
56. Woll PJ, Crowther D, Johnson PW, Soukop M, Harper PG, Harris M, Brampton MH and Newlands ES (1995) Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 72:183-184.
57. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cell with mutant p53 alleles. Cell 70:937-948.